Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Markets

Trump’s Tariff Threats Target Big Pharma, But Tax Reforms May Hold the Key to U.S. Manufacturing Growth

by Team Lumida
May 7, 2025
in Markets
Reading Time: 5 mins read
A A
0
Fed Official Warns of Inflation Risks Under Trump Presidency

"Donald Trump" by Gage Skidmore is licensed under CC BY-SA 2.0

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com

  • President Trump’s proposed tariffs on the pharmaceutical industry aim to bring more drug production back to the U.S., but experts argue that tax reforms could be a more effective long-term solution.
  • Pharma companies historically moved offshore not for cheap labor but to benefit from lower corporate tax rates in countries like Ireland, which offered a 12.5% rate compared to the U.S.’s pre-2017 rate of 35%.
  • Trump’s 2017 tax reforms, which lowered the U.S. corporate tax rate to 21% and introduced a minimum tax on foreign earnings, have already made U.S. production more attractive.
  • Industry leaders, including CEOs from Eli Lilly, Pfizer, and Johnson & Johnson, are pushing for further tax incentives, such as a 15% tax rate for U.S. manufacturing, restored R&D deductions, and more favorable interest deductions for domestic facility investments.
  • Generic drug production, which has largely shifted to India and China, poses a unique challenge due to its low margins. Tariffs on generics could worsen drug shortages and quality issues in the U.S.

What Happened?

President Trump’s administration is ramping up pressure on the pharmaceutical industry with proposed tariffs aimed at reshoring drug production. While tariffs have prompted some companies to expand U.S. operations, experts argue that tax reforms would be a more sustainable way to encourage long-term investment.

Pharma companies have historically moved operations offshore to benefit from lower tax rates, not cheaper labor. Trump’s 2017 tax reforms reduced the corporate tax rate and introduced measures like the Global Intangible Low-Taxed Income (GILTI) regime, which taxed foreign earnings. However, loopholes still allow companies to report U.S.-generated profits in low-tax jurisdictions.

Congress is now considering additional tax incentives, such as a 15% tax rate for U.S. manufacturing and restored R&D deductions, to further boost domestic production. At the same time, policymakers are exploring ways to tighten GILTI rules to ensure they apply only to genuinely foreign profits.


Why It Matters?

The pharmaceutical industry is one of the few sectors where reshoring is feasible due to its high margins and reliance on intellectual property rather than cheap labor. However, tariffs alone may not be enough to drive meaningful change.

Tax reforms, such as lowering the tax rate for U.S. manufacturing and restoring R&D incentives, could provide a more effective and sustainable framework for reshoring. These measures would not only encourage investment but also ensure that profits are reported and taxed in the U.S.

For generic drug production, which has largely moved to India and China, tariffs could exacerbate existing issues like drug shortages and quality concerns. Direct financial support from the government may be necessary to bring portions of this industry back to the U.S.


What’s Next?

Pharma companies have already announced significant U.S. investments, with Eli Lilly, Roche, and Johnson & Johnson pledging a combined $132 billion to expand domestic operations. However, the sustainability of these investments will depend on whether Congress enacts further tax reforms.

Policymakers will also need to address the unique challenges of the generic drug industry, potentially through targeted financial support or incentives. The outcome of these efforts will shape the future of U.S. pharmaceutical manufacturing and its ability to compete globally.

Source
Previous Post

SEC Delays Decision on Litecoin ETF, Requests Public Comments

Next Post

Mark Zuckerberg Envisions a Future Where AI Friends Outnumber Human Companions

Recommended For You

Tesla Plans to Unveil Cheaper Version of the Model Y

by Team Lumida
19 hours ago
Major Tech Platforms Face Malaysian Licensing Deadline as X and Google Hold Out

Key Takeaways Powered by lumidawealth.com Tesla is set to unveil a more affordable base version of the Model Y to offset the loss of the up to $7,500 federal...

Read more

SEC Probes AppLovin Over Data-Collection Practices

by Team Lumida
19 hours ago
SEC Probes AppLovin Over Data-Collection Practices

Key Takeaways Powered by lumidawealth.com The U.S. Securities and Exchange Commission (SEC) is investigating AppLovin Corp. for allegedly violating platform partners’ service agreements by using unauthorized data-collection methods to...

Read more

Citadel’s Ken Griffin Calls Rush to Gold as Safer Asset ‘Concerning’

by Team Lumida
19 hours ago
gold and black metal tool

Key Takeaways Powered by lumidawealth.com Ken Griffin of Citadel expressed concern that investors increasingly view gold as a safer asset than the U.S. dollar, signaling growing worries about U.S....

Read more

Boeing Said to Prepare for 737 Output Hike

by Team Lumida
2 days ago
a tall building with a sign on top of it

Key Takeaways Powered by lumidawealth.com Boeing is guiding suppliers that 737 Max production could rise to 42 jets/month as soon as October, with further pushes planned (targeting ~53/month by...

Read more

Terraformation’s Tree‑Subscription Service

by Team Lumida
4 days ago
A cell phone sitting on top of a wooden table

Key Takeaways Powered by lumidawealth.com Terraformation (founded by former Reddit CEO Yishan Wong) launched a $25/month subscription that funds planting and multi‑year care for biodiverse forests, with initial projects...

Read more

Boeing to Take Billions in Charges After 777X Delay

by Team Lumida
5 days ago
a tall building with a sign on top of it

Key Takeaways Powered by lumidawealth.com Boeing’s 777X certification and entry‑into‑service have slipped further, now expected in 2027 (early or H2 depending on the read), prompting analysts to forecast a...

Read more

Google to Build $4B Data Center in Arkansas

by Team Lumida
5 days ago
China Stimulus: Enough to Sway Markets?

Key Takeaways Powered by lumidawealth.com Google will invest $4 billion to build a data center on >1,000 acres in West Memphis, Arkansas — its first facility in the state....

Read more

Samsung, SK Hynix Rally on OpenAI Stargate Partnership

by Team Lumida
6 days ago
black and white city building during daytime

Key Takeaways Powered by lumidawealth.com Samsung and SK Hynix struck letters of intent with OpenAI to supply chips and infrastructure for OpenAI’s Stargate AI‑data‑center initiative, sending both stocks to...

Read more

JPMorgan Boosts Alibaba Price Target to Street High on AI, Cloud

by Team Lumida
6 days ago
Tax-Loss Harvesting Surge: JPMorgan’s $15 Billion Windfall

Key Takeaways Powered by lumidawealth.com JPMorgan raised its price target for Alibaba’s Hong Kong shares to HK$240 (end‑2026), implying ~36% upside from the recent close and the highest Street...

Read more

Boeing Begins Early Work on 737 MAX Successor

by Team Lumida
1 week ago
a building with palm trees in front of it

Key Takeaways Powered by lumidawealth.com Boeing has initiated early-stage development of a new single-aisle aircraft to replace the 737 MAX, including flight-deck design work and engine discussions with Rolls‑Royce;...

Read more
Next Post
a white square with a blue logo on it

Mark Zuckerberg Envisions a Future Where AI Friends Outnumber Human Companions

China’s Bold Economic Moves: What You Need to Know Now

China Cuts Rates and Injects $139 Billion in Liquidity to Counter U.S. Tariffs

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Pfizer’s $43 Billion Gamble: What It Means for Cancer Research

Pfizer’s $43 Billion Gamble: What It Means for Cancer Research

August 19, 2024
photo of pub set in room during daytime

TGI Fridays’ Fall from Grace: Iconic Restaurant Chain’s Bankruptcy Marks End of Casual Dining Era

December 27, 2024
white house under maple trees

The Hidden Crisis in America’s Housing Market: What You Need to Know

June 28, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018